NIH R01 · 2025
PROJECT ABSTRACT: Prostate cancer is the most common cancer diagnosis in men, with approximately 300,000 new cases per year, marked by exceptionally heterogeneous prognosis across patients. We are now a decade into the era of clinically available genomic biomarker tests to improve clinical prognostic estimates and help guide decision-making after diagnosis of prostate cancer. Three RNA-based tests from prostate tissues are currently included in NCCN guidelines, and they have recently been joined by the first predictive biomarker derived from pathology artificial intelligence (PAI) analysis of standard H&E-stained cancer tissue. However, current genomic tests offer limited insights into…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.